Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06586658
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-07
Brief Title:
Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or RelapsedMetastatic CD70 Inoperable Renal Cells
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Exploratory Clinical Study of the Safety and Efficacy of Anti-CD70-CAR-T Cell Injection in Patients With Locally Advanced or RelapsedMetastatic Renal Cell Carcinoma With CD70 Inoperable
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an investigator-initiated trial to evaluate the role of anti-CD70-CAR T cells in locally advanced or recurrentmetastatic renal cell carcinoma that is inoperable
Detailed Description:
This is an investigator-initiated trial to evaluate the role of anti-CD70-CAR T cells in locally advanced or recurrentmetastatic renal cell carcinoma that is inoperable
Study intervention consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
Interim analysis will be performed when the last participant finishes the visit of 12 weeks after CAR-T cells infusion
Study intervention consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
Interim analysis will be performed when the last participant finishes the visit of 12 weeks after CAR-T cells infusion
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None